BONESUPPORT HOLDING AB (publ) – Publishes Q3 2023 interim report
Published: 2023-10-26
BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the third quarter 2023.
CONTINUED STRONG GROWTH IN BOTH SEGMENTS
JULY – SEPTEMBER 2023
- Net sales increased by 87 percent (76 percent at constant exchange rates) and amounted to SEK 158.2 million (84.6).
- The North America (NA) segment reported a sales growth of 115 percent (102 percent at constant exchange rate).
- The Europe & Rest of the World (EUROW) segment reported a sales growth of 31 percent (26 percent at constant exchange rates).
- The gross margin amounted to 92.1 percent (90.8).
- The operating result before effects from the Group’s incentive programs amounted to SEK +24.6 million (-4.4). Reported operating result amounted to SEK +14.9 million (-13.9).
- Earnings per share before dilution were SEK +3.52 (-0.23). Adjusted for deferred tax receivables on tax losses carried forward, which have been reported for the first time this period, the earnings per share before dilution were SEK +0.18.
- Earnings per share after dilution were SEK +3.47 (-0.23). Adjusted for deferred tax receivables on tax losses carried forward, which have been reported for the first time this period, the earnings per share after dilution were SEK +0.18.
JANUARY – SEPTEMBER 2023
- Net sales increased by 85 percent (75 percent at constant exchange rates) and amounted to SEK 418.3 million (225.6).
- The North America (NA) segment reported a sales growth of 117 percent (103 percent at constant exchange rate).
- The Europe & Rest of the World (EUROW) segment reported a sales growth of 31 percent (26 percent at constant exchange rates).
- The gross margin amounted to 91.4 percent (90.1)
- The operating result before effects from the Group’s incentive programs amounted to SEK +42.8 million (-26.1). Reported operating result amounted to SEK +21.6 million (-45.3).
- Earnings per share before dilution were SEK +3.61 (-0.74). Adjusted for deferred tax receivables on tax losses carried forward, which have been reported for the first time this period, the earnings per share before dilution were SEK +0.26.
- Earnings per share after dilution were SEK +3.56 (-0.74). Adjusted for deferred tax receivables on tax losses carried forward, which have been reported for the first time this period, the earnings per share after dilution were SEK +0.26.
“87 percent sales growth and the first quarter with positive cash flow.” Emil Billbäck, CEO
EVENTS DURING THE REPORTING PERIOD
- During August, the last patient was enrolled to the SOLARIO study.
- During the quarter, the Company recognized deferred tax receivables on its tax losses carried forward in the balance sheet for the first time, amounting to SEK 230 million.
EVENTS AFTER THE REPORTING PERIOD
In October 2023, BONESUPPORT received Breakthrough device designation from the FDA for CERAMENT V for the indication of bone infection.
For more information contact:
BONESUPPORT Holding AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70
Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com
Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se
This information is information that BONESUPPORT Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-10-26 08:00 CEST.
About BONESUPPORT™
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 329 million in 2022. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.
Attachments